TGTX
TG THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$53.30
−1.24%Oct 12, 2026, 11:30 UTC
TG THERAPEUTICS, INC. announced publication of a five-year comparative analysis of BRIUMVI versus ocrelizumab and ofatumumab in relapsing multiple sclerosis.
Source:Oct 8, 2026, 11:30 UTC
TG Therapeutics announced the schedule of data presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, including a late-breaking oral presentation on initial Phase 1 results for azer-cel in patients with primary progressive multiple sclerosis and several presentations on BRIUMVI.
Source:Sep 28, 2026, 13:09 UTC
Kuehn Law, PLLC is investigating whether certain officers and directors of TG Therapeutics, Inc. breached their fiduciary duties to shareholders.
Source:Aug 23, 2026, 08:10 UTC
Deutsche Bank AG acquired a new stake of 235,481 shares in TG Therapeutics, Inc., valued at approximately $12.9 million, as disclosed in a Form 13F filing.
Source:Aug 3, 2026, 11:00 UTC
TG Therapeutics announced its financial results for the second quarter of 2026, reporting total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million.
Jul 7, 2026, 14:01 UTC
TG Therapeutics begins a Phase II study with Briumvi in adult patients with treatment-resistant schizophrenia.
Source:Jun 10, 2026, 14:21 UTC
TG Therapeutics announced positive phase I data for subcutaneous Briumvi in myasthenia gravis and initiated a phase II study in MG.
Source:Jun 4, 2026, 16:01 UTC
TG Therapeutics announced positive Phase I data for subcutaneous Briumvi, showing over 60% bioavailability, sustained drug exposure, and good tolerability.
Source:Jun 3, 2026, 11:30 UTC
TG Therapeutics announced positive Phase 1 trial results for a subcutaneous formulation of BRIUMVI (ublituximab-xiiy).
Source: